5A. John Camm ,Gregory Y. H. Lip , Raffaele De Caterina ,et al. 2012 focused update of the ESC Guidelines for the manage- ment of atrial fibrillation E']. European Heart Journal, 2012, 33:2719-2747 . 被引量：1
6Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patientswith atrial ibrillation[J]. N Engl J Med, 2009,361: 1139-1151. 被引量：1
7Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009,361(12) : 1139-1151. 被引量：1
8Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/ AHA/HRS focusedupdate on the management of patients with atrial fibrillation (update on Dabigatran) : a report of the Ameri- can College of Cardiology Foundation/American Heart Associa- tion Task Force on practice guidelines[J]. Circulation, 2011, 123(10) :1144-1150. 被引量：1
9Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin innonvalvular atrial fibrillation [J]. N Engl J Med,2011, 365(10): 883-891. 被引量：1
10Granger CB, Alexander JH, MeMurray JJ, et al. Apixaban versus warfarinin patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11): 981-992. 被引量：1
